Clinical trials: Hepatic Cirrhosis
Cirrhosis Portal
Portal Vein Flow Velocity as a Screening Tool for Oesophageal Varices in Cirrhotic Patients
Portal vein flow velocity as screening tool for prediction of oesophageal varices in cirrhotic patient without upper endoscopy
- Trial name
- Portalflow (NCT05228509)
- Where
- 2 sites in Egypt
- Volunteers
- 75 people
- Sponsor
- Peter atef
Cirrhosis
To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
The study will be conducted on patients admitted to Department of Hepatology from MARCH 2015 to DECEMBER 2016 at ILBS, New Delhi.All patients presenting to ILBS fulfilling the inclusion criteria will be included in the study and…
- Trial name
- NCT02465619
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
Liver Failure, Cirrhosis
Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial
The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,.
- Trial name
- NCT00420134
- Testing
- injection of progenitor of hepatocyte drived from Mesenchymal stem cell
- Where
- 2 sites in Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Cirrhosis
Thrombin Generation Test in Patient With Liver Cirrhosis
Cirrhotic patients are patients with high morbidity and mortality, it is very important for determining the prognosis of these patients. The importance increases when these patients waiting for a liver transplant.
- Trial name
- NCT02484534
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- HaEmek Medical Center, Israel
Primary Biliary Cirrhosis
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
The study is designed to evaluate the safety and efficacy of intravenous administration of bone marrow derived mesenchymal stem cells for patients with refractory primary biliary cirrhosis (PBC).
- Trial name
- MSCsTreatPBC (NCT01440309)
- Testing
- Biological: mesenchymal stem cell, ursodeoxycholic acid
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Robert Chunhua Zhao, MD, PhD
Hepatopulmonary Syndrome
Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China
to investigate the prevalence of hepatopulmonary syndrome in cirrhosis patients caused by Hepatitis B in western China
- Trial name
- NCT03435406
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Southwest Hospital, China
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Liver Disease, Liver Cirrhosis
Hepatocyte Matrix Implant Study
This clinical investigation of the hepatocyte matrix implant is an evaluation blinded non-randomized and monocentric pilot study of Phase I, which is conducted as a therapeutic investigation.
- Trial name
- HMI (NCT00935454)
- Testing
- Hepatocyte matrix implantation
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Baermed
Primary Biliary Cholangitis, Liver Cirrhosis
Austrian PBC Registry
The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden.
- Conditions
- Primary Biliary Cholangitis, Liver Cirrhosis, Portal Hypertension
- Trial name
- PBC-AUT (NCT07598669)
- Where
- 11 sites in Austria
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Primary Biliary Cholangitis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants with Primary Biliary Cholangitis (PBC).
- Trial name
- NCT04594694
- Testing
- Obeticholic acid, Bezafibrate 200 MG, Bezafibrate 400 MG
- Where
- 33 sites in Australia, Belgium and 15 more
- Volunteers
- 75 people
- Sponsor
- Intercept Pharmaceuticals
Non-alcoholic Steatohepatitis
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is…
- Trial name
- NCT03987451
- Testing
- Semaglutide
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Cirrhosis, Ascites Hepatic
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
The development of ascites is a landmark event in the natural history of cirrhosis and signifies a grim prognosis. Portal hypertension and splanchnic arterial vasodilatation are the major contributors in the development of…
- Trial name
- NCT05014594
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Where
- India
- Volunteers
- 44 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Hepatitis B, Chronic Hepatitis C
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
This is a multi-center cross-sectional study in which the Real-time Tissue Elastography® measurements will be collected prospectively from patients with chronic hepatitis B or C virus presenting for liver biopsy.
- Trial name
- FIBROELAST (NCT01360879)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Kindai University
Liver Cirrhosis, Variceal Bleeding, Cirrhosis
Underdilated-stent Technique Improves Post-TIPS Encephalopathy
Transjugular intrahepatic portosystemic shunt (TIPS) is a critical therapeutic approach for managing esophagogastric variceal bleeding and refractory ascites in decompensated cirrhosis patients.
- Conditions
- Liver Cirrhosis, Variceal Bleeding, Cirrhosis, Ascites Hepatic, Hepatic Encephalopathy (HE)
- Trial name
- NCT07349654
- Testing
- 6mm balloon dilation, 8mm balloon dilation
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Cirrhosis, Hepatic Encephalopathy
Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System
The purpose of the current study is to look into the pathogenesis of a severe medical condition causing acute episodes on the central nervous system as seen in majority of patients with liver cirrhosis.
- Trial name
- NCT00424957
- Where
- Denmark
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the…
- Conditions
- Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
- Trial name
- SAMARA (NCT06005012)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Cirrhosis, Hepatic Encephalopathy
The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis
Ascites is the accumulation of fluid within the peritoneal cavity of the abdomen. It is a frequent complication of cirrhosis that is associated with significant morbidity and poor quality of life.
- Conditions
- Cirrhosis, Hepatic Encephalopathy, Ascites, Fatigue
- Trial name
- NCT01777971
- Where
- United States
- Sponsor
- NYU Langone Health
Primary Biliary Cholangitis
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy
- Trial name
- EPICS-IV (NCT07424677)
- Testing
- Saroglitazar Magnesium 1 mg
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Zydus Therapeutics Inc.
Liver Cirrhosis, Chronic Hepatitis C
Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States veterans. Cirrhosis is associated with impaired antibody responses and increased risk of bacterial infections.
- Trial name
- NCT01951209
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- David E. Kaplan, MD MSc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.